2025 has been a stellar year for Lange Neurology, PC. As we close the year, we continue to provide our patients with the highest standard of care and to offer cutting edge therapies for the most pernicious neuromuscular ailments. In addition, we extended our infusion treatments to include therapies that help promote well-being.
Cartesian Therapeutics, Inc. has chosen Lange Neurology, PC as a trial site for its Phase III study of Descates-08 in patients with generalized myasthenia gravis...
Lange Neurology, PC has been designated a trial site by Immunovant, Inc. for its Phase IIb study of IMVT-1402 treatment in adults. Immunovant, Inc. is...
PhenoNet, a clinical-stage biotechnology company developing next-generation therapies for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and related neurodegenerative disorders, has chosen Lange Neurology as...
Immunovant, Inc., a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases, has designated Lange Neurology PC, as a trial site...
Dr. Dale J. Lange attended the 36th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease (ALS/MND) held December 5-7 in San Diego, CA.
Dr. Dale, J. Lange and research coordinators, Samantha Heffernan, FNP-BC, RN and Shannon Stevens, RN, CNRN attended 2025 Annual NEALS Meeting in Clearwater, Florida held...
Lange Neurology is currently recruiting patients of all genders, ages 18 – 100 who have been diagnosed with ALS within the past two years.
Dr. Dale J. Lange, a dual board-certified neurologist with a stellar reputation in the field of neurology, has unveiled Lange Neurology, PC in the heart...
